A Randomized Parallel Controlled Phase II Trial of Recombinant Human Endostatin Added to Neoadjuvant Chemotherapy for Stage III Breast Cancer

Xiangmei Zhang, Zhenzhen Zhang, Miao Cao, Beichen Liu, Motomi Mori, Shiuh Wen Luoh, Raymond Bergan, Yueping Liu, Yunjiang Liu

Research output: Contribution to journalArticlepeer-review

Abstract

This clinical trial evaluated recombinant human endostatin in breast cancer neoadjuvant chemotherapy. Eighty-seven patients with stage III breast cancer randomly received 4 cycles neoadjuvant of TEC (docetaxel, epirubicin, and cyclophosphamide) or recombinant human endostatin + TEC, followed by surgery. The latter significantly improved the overall survival, suggesting a benefit of adding anti-angiogenesis to standard chemotherapy in the treatment of breast cancer.

Original languageEnglish (US)
Pages (from-to)291-299.e3
JournalClinical Breast Cancer
Volume20
Issue number4
DOIs
StatePublished - Aug 2020

Keywords

  • Breast cancer
  • Neoadjuvant therapy
  • Objective response rate
  • Overall survival
  • Recombinant human endostatin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A Randomized Parallel Controlled Phase II Trial of Recombinant Human Endostatin Added to Neoadjuvant Chemotherapy for Stage III Breast Cancer'. Together they form a unique fingerprint.

Cite this